Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine

BMC Veterinary Research

Volumn 10, Issue , 2014, Pages

  Zhou, Chun Xue ^a   Li, Dong ^a   Chen, Ying Li ^a   Lu, Zeng Jun ^a   Sun, Pu ^a   Cao, Yi Mei ^a   Bao, Hui Fang ^a   Fu, Yuan Fang ^a   Li, Ping Hua ^a   Bai, Xing Wen ^a   Xie, Bao Xia ^a   Liu, Zai Xin ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Aluminum hydroxide; FMDV; Poly(I:C); R848

Indexed keywords

ALUMINUM HYDROXIDE; IMIDAZOLE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; CYTOLOGY; DRUG EFFECT; FEMALE; FOOT AND MOUTH DISEASE; IMMUNOLOGY; MOUSE; SPLEEN; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; FEMALE; FOOT-AND-MOUTH DISEASE; IMIDAZOLES; MICE; MICE, INBRED BALB C; POLY I-C; SPLEEN; T-LYMPHOCYTE SUBSETS; VIRAL VACCINES;

EID: 84892180596     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-10-2     Document Type: Article

References (27)

1. Gerner W, Denyer MS, Takamatsu HH, Wileman TE, Wiesmüller KH, Pfaff E, Saalmüller A. Identification of novel foot-and-mouth disease virus specific T-cell epitopes in c/c and d/d haplotype miniature swine. Virus Res 2006, 121:223-228. 10.1016/j.virusres.2006.05.006, 16934904.
2. Sobrino F, Saiz M, Jimenez-Clavero MA, Nunez JI, Rosas MF, Baranowski E, Ley V. Foot-and-mouth disease virus: a long known virus, but a current threat. Vet Res 2001, 32:1-30. 10.1051/vetres:2001106, 11254174.
3. Dunn CS, Donaldson AI. Natural adaption to swine of a Taiwanese isolate of foot-and-mouth disease virus. Vet Rec 1997, 141:174-175. 10.1136/vr.141.7.174, 9290197.
4. Donaldson AI, Alexandersen S, Sorensen JH, Mikkelsen T. Relative risks of the uncontrollable (airborne) spread of FMD by different species. Vet Rec 2001, 148:602-604. 10.1136/vr.148.19.602, 11386448.
5. Patil PK, Bayry J, Ramakrishna C, Hugar B, Misra LD, Natarajana C. Immune responses of goats against foot-and-mouth disease quadrivalent vaccine: comparison of double oil emulsion and aluminiumhydroxide gel vaccines in eliciting immunity. Vaccine 2002, 20:2781-2789. 10.1016/S0264-410X(02)00184-6, 12034105.
6. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672. 10.1016/S0264-410X(00)00498-9, 11257407.
7. Gay NJ, Gangloff M. Structure and function of toll receptors and their Ligands. Annu Rev Biochem 2007, 76:141-165. 10.1146/annurev.biochem.76.060305.151318, 17362201.
8. Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian and cervix cancers. Cancer Immunol Immunother 2010, 59:1877-1884. 10.1007/s00262-010-0914-1, 20820775.
9. Noreen M, Shah MAA, Mall SM, Choudhary S, Hussain T, Ahmed I, Jalil SF, Raza MI. TLR4 polymorphisms and disease susceptibility. Inflamm Res 2012, 61:177-188. 10.1007/s00011-011-0427-1, 22277994.
10. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll- like receptor 7 and 8. Science 2004, 303:1526-1529. 10.1126/science.1093620, 14976262.
11. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012, 122:575-585. 10.1172/JCI61034, 3266798, 22251703.
12. Torii Y, Ito T, Amakawa R, Sugimoto H, Amuro H, Tanijiri T, Katashiba Y, Ogata M, Yokoi T, Fukuhara S. Imidazoquinoline acts as immune adjuvant for functional alteration of thymic stromal allergic T cell response. J Immunol 2008, 181:5340-5349.
13. Van LP, Bardel E, Gregoire S, Vanoirbeek J, Schneider E, Thieblemont N. Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms. Eur J Immunol 2011, 41:1992-1999. 10.1002/eji.201040914, 21480211.
14. Smirnov D, Schmidt JJ, Capecchi JT, Wightman PD. Vaccine adjuvant activity of 3 M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 2011, 29:5434-5442. 10.1016/j.vaccine.2011.05.061, 21641953.
15. Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3 M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 2007, 56:1133-1141. 10.1007/s00262-006-0262-3, 17139492.
16. Tomai MA, Vasilakos JP. TLR-7 and-8 agonists as vaccine adjuvants. Exp Rev Vaccines 2011, 10:405-407.
17. Yang M, Clavijo A, Suarez-Banmann R, Avalo R. Production and characterization of two serotype independent monoclonal antibodies against foot- and-mouth disease virus. Vet Immunol Immunopathol 2007, 115:126-134. 10.1016/j.vetimm.2006.10.002, 17109972.
18. Kim CH, Chan DP, Lee AY. Administration of poly (I: C) improved dermatophagoides farinae-induced atopic dermatitis-like skin lesions in NC/Nga mice by the regulation of Th1/Th2 balance. Vaccine 2012, 30:2405-2410. 10.1016/j.vaccine.2011.11.049, 22119586.
19. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005, 23:5263-5270. 10.1016/j.vaccine.2005.06.024, 16081189.
20. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. Synthetic double-stranded RNA Poly(I: C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005, 79:2910-2919. 10.1128/JVI.79.5.2910-2919.2005, 548446, 15709010.
21. Marathias K, Pinto C, Rodberg G, Preffer F, Wong J, Kradin R. The T cell antigen receptor CD3:CD4 molecular complex is diminished on the surface of pulmonary lymphocytes. Am J Pathol 1994, 145:1219-1227. 1887433, 7977652.
22. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF. Triggering TLR7 in mice induces immune activation and lymphoid system disruption resembling HIV-mediated pathology. Blood 2009, 113:377-388.
23. Batista A, Quattrocchi V, Olivera V, Langellotti C, Pappalardo JS, Di Giacomo S, Mongini C, Portuondo D, Zamorano P. Adjuvant effect of Cliptox on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice. Vaccine 2010, 28:6361-6366. 10.1016/j.vaccine.2010.06.098, 20637310.
24. Ma M, Jin N, Shen G, Zhu G, Liu HJ, Zheng M, Lu H, Huo X, Jin M, Yin G, Ma H, Li X, Ji Y, Jin K. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18. Vet Immunol Immunopathol 2008, 121:1-7. 10.1016/j.vetimm.2007.06.029, 17706296.
25. Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nusenzweig MC, Sreinman RM, Seder RA. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4 + T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and α DEC-CSP in non human primates. Vaccine 2010, 28:7256-7266. 10.1016/j.vaccine.2010.08.098, 3004225, 20846528.
26. Pufnock JS, Cigar M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, Greenberg PD. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhance generation of CD8 + T cells retaining CD28. Blood 2011, 117:6542-6551. 10.1182/blood-2010-11-317966, 3123022, 21493800.
27. Wick DA, Martin SD, Nelson BH, Webb JR. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 2011, 29:984-993. 10.1016/j.vaccine.2010.11.036, 21115055.